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Tannic acid is a polyphenolic compound that could be labeled with technetium-99m. To produce about 90% yield of 99mTc-tannic
acid in acidic media (pH), the conditions required were 150µg tin chloride, 30min reaction time, and 200µg of the substrate.
99mTc-tannic was stable for 6h. Oral biodistribution of 99mTc-tannic showed that it concentrated in the stomach ulcer to reach
about 50% of the total injected dose at 1 h after orall administration. This concentration of 99mTc-tannic in stomach ulcer may be
suﬃcient to radio-image the presence of ulcer in the stomach.
1.Introduction
Theuseofradioisotopesandradiationisindispensableinthe
research of life science, especially in pharmaceutical sciences.
In vitro and in vivo diagnostic researches in nuclear medicine
use radioisotopes and radiopharmaceuticals. Many tracers
wereusedlikeTC-99m,Re-181,I-131,andothers[1–3].Also
many compounds were subjected to be labeled with these
radioisotopes like MAG3, MDP, DTPA and others [4–6].
Many items should be in consideration for radio-imaging,
for example, radiopharmaceutical development for the kid-
neys must focus on achieving high-target selectivity and
binding aﬃnity, stability and slow metabolism in vivo,a n d
minimal nonspeciﬁc accumulation and urinary excretion
[7].
A peptic ulcer is deﬁned as mucosal erosions equal to or
greater than 0.5 cm of an area of the gastrointestinal tract
that is usually acidic and thus extremely painful. As many as
80%ofulcersareassociatedwithHelicobacterpylori[8–11],a
spiral-shaped bacterium that lives in the acidic environment
of the stomach, however only 20% of those cases go to a
doctor. Ulcers can also be caused or worsened by drugs
such as aspirin and other nonsteroidal anti-inﬂammatories
(NSAIDs)[12].Contrarytogeneralbelief,morepepticulcers
arise in the duodenum (ﬁrst part of the small intestine, just
afterthestomach)thaninthestomach.About4%ofstomach
ulcers are caused by a malignant tumor, so multiple biopsies
are needed to exclude cancer [13, 14].
Amajorcausativefactorofgastricandofduodenalulcers
is chronic inﬂammation due to Helicobacter pylori that col-
onizes the antral mucosa. Thus, the bacterium can cause a
chronic active gastritis (type B gastritis), resulting in a defect
in the regulation of gastrin production by that part of the
stomach, and gastrin secretion can either be decreased (most
cases) resulting in hypo- or achlorhydria or increased [15].
Gastrin stimulates the production of gastric acid by parietal
cells and, in H. pylori colonization responses that increase
gastrin [13, 15], the increase in acid can contribute to the
erosionofthemucosaandthereforeulcerformation[10,11].
Another major cause is the use of NSAIDs. The gastric
mucosa protects itself from gastric acid with a layer of mu-
cus, the secretion of which is stimulated by certain pros-
taglandins. NSAIDs block the function of cyclooxygenase
1 (cox-1), which is essential for the production of these
prostaglandins [12, 16–19].
Diagnosis of peptic ulcer mainly by An esophagogastro-
duodenoscopy (EGD), a form of endoscopy, also known as a
gastroscopy,iscarriedoutonpatientsinwhomapepticulcer
is suspected. By direct visual identiﬁcation, the location and
severity of an ulcer can be described. Moreover, if no ulcer
is present, EGD can often provide an alternative diagnosis
[10, 11]. The diagnosis of Helicobacter pylori can be made2 ISRN Pharmaceutics
by Urea breath test (noninvasive and does not require EGD).
So ulcer can be diagnosis by
(1) direct culture from an EGD biopsy specimen; this is
diﬃcult to do, and can be expensive. Most labs are
not set up to perform H. pylori cultures,
(2) direct detection of urease activity in a biopsy speci-
men by rapid urease test,
(3) measurement of antibody levels in blood (does not
require EGD). It is still somewhat controversial
whether a positive antibody without EGD is enough
to warrant eradication therapy,
(4) stool antigen test,
(5) histological examination and staining of an EGD
biopsy.
Tannic acid (a commercial form of tannin) is a polyphe-
noliccompound[20].Itsweakacidity(pKa around10)isdue
to these phenol groups in the structure. Its structure is based
mainly on glucose esters of gallic acid. It is a yellow to light
brown amorphous powder which is highly soluble in water.
Tannic acid is a basic ingredient in the chemical staining of
wood. The tannic acid or tannin is already present in woods
like oak, walnut, and mahogany. Tannic acid can be applied
to woods low in tannin so chemical stains that require tannin
content will react. Tannic acid is the most common mordant
for cellulose ﬁbers such as cotton. Tannin is often combined
with alum and/or iron. The tannin mordant should be done
ﬁrst as metal mordants combine well with the ﬁber-tannin
complex. The presence of tannic acid in the bark of redwood
(Sequoia)isastrongnaturaldefenseagainstwildﬁre,decom-
position and infestation. It is found in the seeds, bark, cones,
and heartwood [21].
This study was conducted to label tannic acid with te-
chentium-99m, studying factors aﬀect labeling yield and
evaluatethelabeledcompoundwithchromatographicmeth-
ods. It also studied the biodistribution of oral or interav-
enous 99mTc-tannic acid in normal or mice diseased with
stomach ulcer.
2.MaterialsandMethods
2.1. Drugs and Chemicals
(1) Tchentium-99m was obtained as saline eluent of an
expired Mo column.
(2) Tannic acid was supplied from ICN Chemical Com-
pany, USA.
(3) Tin chloride was purchased from Sigma Chemical
Company, USA.
(4) All other chemical reagents were of analytical grade
(AR), obtained from reputed manufacturers.
2.2. Animals. Female Swiss Albino mice weighing 20–25gm
were purchased from the Institute of Eye Research Cairo,
Egypt. The animals were kept at constant environmental and
nutritional conditions throughout the experimental period
and kept at room temperature (22±2)◦Cw i t ha1 2h ro n / o ﬀ
lightschedule.Animalswerekeptwithfreeaccesstofoodand
water all over the experiment.
2.3. Methods
2.3.1. Labeling Procedure and Requirement. 99mTc-tannic
acid was prepared by the following procedures [22]. 1mg
tannic acid was dissolved in 1mL purged distilled water
with stirring. Tin chloride was added to tannic acid solution
in evacuated vial with Hamilton syringe and approximately
200–400MBq 99mTc at room temperature. After a speciﬁed
interval of time, chromatographic analysis was developed
using paper chromatography ascending techniques [23].
The yield of the reaction and the radiochemical purity
were determined by paper chromatography using acetone as
mobilephasetodistinguishbetweenfreepertechnetateatthe
top and both complex and reduced colloids near the point of
spotting. On the other hand, Thin Layer Chromatography
using 2N HCl as a mobile phase diﬀerentiates between
reduced colloids which persist near the point of spotting and
both complex and free, which move towards the front of
chromatogram.
2.4. Factors Aﬀecting % Labeling Yield. This experiment was
conducted to study the diﬀerent factors that aﬀect labeling
yield such as (1) tin content, (2) substrate content, (3) pH of
the reaction, and (4) reaction time.
In the process of labeling, trials and errors were per-
formed for each factor under investigations till obtains the
optimumvalue.Theexperimentwasrepeatedwithallfactors
kept at optimum changing except the factor under study, till
the optimal conditions are achieved [24].
2.5. In Vitro Stability. This experiment was conducted to
determine the stability of 99mTc-tannic acid after labeling
and the impact of time on that compound. The yield was
measuredatdiﬀerenttimeintervals(1,2,6,12and24h)after
labeling [25].
2.6. Induction of Ulcer in the Stomach of Mice. There are
many methods for induction of ulcer in laboratory animals.
The simplest one in mice is the oral administration of ethyl
alcohol 1mL/mice. After 1-2h the stomach showed disten-
sion of stomach and symptoms of ulcer appeared [26].
2.7. In Vivo Biodistribution
2.7.1. In Normal Mice. In vivo biodistribution studies were
performed using 3 groups each comprise six mice. Each an-
imal was injected in the tail vein with 0.2mL solution con-
taining 200–400KBq of 99mTc-tannic acid freshly prepared.
The mice were kept in metabolic cages for the required
time. Each group was subjected to scariﬁcation by cervical
dislocation at the recommended time (15min, 1hr or 2hr)
after injection. Organs or tissues of interest were removed,
washed with saline, weighted, and counted. Correction was
made for background radiation and physical decay during
the experiment. The weights of blood, bone, and musclesISRN Pharmaceutics 3
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Figure 1: Eﬀect of tin chloride content on the radiochemical yield
99mTc-tannic acid.
were assumed to be 7, 10, and 40% of the total body weight,
respectively, [27].
2.7.2.InUlcer-BearingMice. Biodistributionof 99mTc-tannic
acid was carried out in two groups of animals each group
consists of 18 ulcer-bearing mice. The ﬁrst group received
200–400KBq of 99mTc-tannic/mice intravenously in the tail
vein and the other group received oral 200–400KBq of
99mTc-tannic/mice using oral tube. Each group subdivided
to 3 subgroups of 6 mice each. Animals in each group were
kept in metabolic cages for scariﬁcation at its required time,
after 15min, 1h or 2h after injection of the labeled drug.
Sacriﬁcation of mice was done by cervical dislocation and
the organs or tissues of interest were isolated, weighted and
counted for its uptake of radioactivity. The counting tubes,
including a standard equivalent to 1% of the injected dose,
were assayed in a well type NaI (TI) gamma counter and the
results were calculated as percentages of injected dose (ID)
per gram tissue. The ﬁnal results were expressed as mean ±
one standard error [28].
2.8. Statistical Analysis. The results are expressed as means ±
SEM for the indicated number of diﬀerent experiments. The
statisticalsigniﬁcanceofdiﬀerenceswasassessedbyunpaired
Student’s t-test P<0.05.
3. Results andDiscussion
3.1. Paper Chromatography. The analysis of chromato-
graphic data revealed the high percentage labeling yield of
99mTc-tannic acid. Free pertechnetate was obtained from
paper acetone chromatogram. Colloid was obtained from
2N HCl chromatogram. Complex 99mTc-tannic acid was
obtained by subtracting % colloid from % activity obtained
near the spotting in acetone chromatogram.
3.2. Factors Aﬀecting Labeling Yield
3.2.1. Tin Content. Results obtained in this study showed
the high yield obtained for 99mTc-tannic acid using tin
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Figure 2: Eﬀect of tannic acid content on the labeling yield.
Table 1: Eﬀect of time on the stability of 99mTc-tannic acid.
Time after
labeling (h)
% Labeled
compound %F r e e99mTc % Colloid
1h 95.5 ± 0.52 2.5 ± 0.05 2.0 ± 0.05
2h 95.1 ± 0.25 2.7 ± 0.25 2.2 ± 0.05
6h 95.2 ± 0.25 2.8 ± 0.25 2.0 ± 0.45
12h 94.7 ± 0.50 2.9 ± 0.25 2.1 ± 0.50
24h 94.5 ± 0.30 2.1 ± 0.15 3.2 ± 0.35
Values represent the mean ± SEM n = 6.
chloride as reducing agent (Figure 1). It was observed that
the radiochemical yield signiﬁcantly increased by increasing
theamountoftinfrom10µgto150µg(o ptim umc ont ent)at
which maximum labeling yield was obtained. By increasing
the amount of tin to 200µg, the yield showed signiﬁcant
decrease in % complex 99mTc-tannic acid. A signiﬁcant
reduction in the labeling yield was noted by decreasing the
concentration of tin below 100µg may be explained as at low
concentrations of tin, not all 99mTc was reduced. While by
increase the tin content to 200µg colloid may be increased
and hence, % labeled complex decreased [29].
3.2.2.EﬀectofSubstrateContent. Theinﬂuenceoftannicacid
content as a substrate on the labeling yield using tin chloride
was shown in Figure 2. The increase of the concentration
of tannic acid was accompanied by a signiﬁcant increase
in the labeling yield, where it reached above 95% at 50µg
of tannic acid. Increasing the amount of tannic acid above
50µgd o e sn o ta ﬀecting the labeling yield. Increasing the
concentration of starting material is usually increases the
total incorporation of 99mTc-tannic acid since there is a
minimum limit to the volume used [30]. 50µg of tannic acid
was required to obtain maximum labeling yield, below this
concentration signiﬁcant decrease in the yield.
3.2.3. Eﬀect of pH. In order to reach the suitable pH value
for maximum radiochemical yield, labeling of tannic acid
with 99mTc was carried out at diﬀerent pH values ranging
from2–12.Thetestwasperformedusing50µgoftannicacid,4 ISRN Pharmaceutics
Table 2: Biodistribution of 99mTc-tannic acid in normal mice.
Organs and Body ﬂuids
Percent I.D./gram organ
Time after injection
15min 1hr 2hr
Blood 18.5 ± 1.10 11.2 ± 0.20∗ 7.2 ± 0.04∗
Bone 4.1 ± 0.05 3.6 ± 0.10∗ 1.4 ± 0.10∗
Muscle 3.0 ± 0.01 2.9 ± 0.02∗ 1.9 ± 0.10
Liver 8.1 ± 0.05 7.7 ± 0.15∗ 5.4 ± 0.16∗
Lung 6.0 ± 0.10 4.5 ± 0.12∗ 2.3 ± 0.20∗
Heart 5.1 ± 0.50 3.6 ± 0.50∗ 1.3 ± 0.01∗
Stomach 5.0 ± 0.90 6.5 ± 0.60 3.4 ± 0.16∗
Intestine 7.0 ± 0.50 5.4 ± 0.30∗ 4.1 ± 0.10∗
Kidney 2.7 ± 0.40 4.6 ± 0.60 4.2 ± 0.30∗
Spleen 0.5 ± 0.02 0.9 ± 0.24∗ 0.8 ± 0.2
Values represent mean ± SEM n = 10
∗signiﬁcantly diﬀerent from previous value of each organ using unpaired
Student’s t-test (P<0.05).
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Figure 3: Eﬀect of pH of the reaction medium on the labeling yield
of 99mTc-tannic acid.
100µL of 0.5M phosphate buﬀer of pH7 at 30min reaction
time. The experiment was repeated using 100µLo fe a c h
buﬀer at diﬀerent pH values. As shown in Figure 3,p H7i s
the optimum pH at which the maximum yield was obtained
(95.5%). Also, it was observed that at pH 2 or 4, the yield was
95%, while at pH values 9 and 12; the yield was 57%, 50%,
respectively. There was signiﬁcant diﬀerence between all pH
values of the reaction mediums.
3.2.4.EﬀectofReactionTime. Figure 4showstherelationship
betweenthereactiontimeandtheyieldof 99mTc-tannicacid.
Radiochemical yield was signiﬁcantly increased from 35% to
95.5% with increasing reaction time from 1min to 30min.
Extendingthereactiontimemorethan30mindoesnotaﬀect
theradiochemicalyield.Theeﬃciencyofreducingagentmay
be aﬀected by time and thus yield decreased [31].
3.3. In Vitro Stability of 99mTc-Tannic Acid. In the present
experiment, a very slight decrease in the stability of 99mTc-
tannic acid from 95.5% to 94.5% at 24h after labeling
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Figure 4: Eﬀect of reaction time on the % labeling yield of 99mTc-
tannic acid.
Table 3: Intravenous biodistribution of 99mTc-tannic acid in ulcer-
bearing mice.
Organs and body ﬂuids
Percent I.D./gram organ
Time after injection
15min 1hr 2hr
Blood 18.0 ± 1.10 10.1 ± 0.20∗ 8.0 ± 0.04∗
Bone 6.0 ± 0.05 3.4 ± 0.10∗ 3.5 ± 0.10∗
Muscle 2.9 ± 0.01 4.0 ± 0.02∗ 7.2 ± 0.10
Liver 9.0 ± 0.05 2.0 ± 0.15∗ 1.1 ± 0.16∗
Lung 2.2 ± 0.10 1.3 ± 0.12∗ 0.1 ± 0.20∗
Heart 4.7 ± 0.50 2.7 ± 0.50∗ 1.3 ± 0.01∗
Stomach 14.2 ± 0.90 7.0 ± 0.60 15.0 ± 0.16∗
Intestine 7.3 ± 0.50 7.5 ± 0.30 6.0 ± 0.10∗
Kidney 5.0 ± 0.40 7.0 ± 0.60 4.5 ± 0.30∗
Spleen 3.0 ± 0.02 1.2 ± 0.24∗ 1.1 ± 0.2
Values represent mean ± SEM n = 6
∗Signiﬁcantly diﬀerent from previous value of each organ using unpaired
Student’s t-test (P<0.05).
was observed. Approximately, a constant labeling yield was
observed at all time intervals after labeling, as the yield was
95.5, 95.1, 95.2, 94.7 and 94.5% at 1h, 2h, 6h, 12h and 24h,
respectively, as shown in Table 1.
3.4. Biodistribution of 99mTc-Tannic Acid
3.4.1. In Normal Mice. Biodistribution study of 99mTc-
tannic acid in normal mice showed that 99mTc-tannic acid
was distributed rapidly in blood, liver, lung and intestine at
15min after injection. After 1h, 99mTc-tannic acid uptake
was signiﬁcantly decreased in organs like blood, heart,
liver and intestine. However, 99mTc-tannic acid uptake was
signiﬁcantly increased in stomach after 1h. At 2h after
injection, the majority of tissues showed signiﬁcant decrease
in 99mTc-tannic acid uptake as shown in Table 2.ISRN Pharmaceutics 5
Table 4: Oral administration of 99mTc-tannic acid in ulcer-bearing
mice.
Organs andbody ﬂuids
Percent I.D./gram organ
Time after injection
15min 1hr 2hr
Blood 8.5 ± 1.10 7.0 ± 0.20∗ 3.5 ± 0.04∗
Bone 4.0 ± 0.05 3.0 ± 0.10∗ 2.0 ± 0.10∗
Muscle 3.0 ± 0.01 2.0 ± 0.02∗ 2.2 ± 0.10
Liver 3.5 ± 0.05 2.1 ± 0.15∗ 3.2 ± 0.16∗
Lung 2.1 ± 0.10 3.1 ± 0.12∗ 3.5 ± 0.20∗
Heart 1.0 ± 0.50 4.0 ± 0.50∗ 5.0 ± 0.01∗
Stomach 18.0 ± 0.90 50.0 ± 0.60 20.0 ± 0.16∗
Intestine 4.0 ± 0.50 14.0 ± 0.30∗ 7.0 ± 0.10∗
Kidney 1.0 ± 0.40 2.5 ± 0.60 3.5 ± 0.30∗
Spleen 1.0 ± 0.02 1.5 ± 0.24∗ 2.5 ± 0.20
Values represent mean ± SEM n = 6
∗Signiﬁcantly diﬀerent from previous value of each organ using unpaired
Student’s t-test (P<0.05).
3.4.2. In Ulcer Bearing Mice
(1)IntravenousRoute. Theresultsofthisexperimentshowed
that the sites of greatest uptake of 99mTc-tannic acid after
15 minutes after injection were the blood and stomach (18
and 14.2), respectively. Table 3 shows that the concentration
of 99mTc-tannic acid was the lowest in muscle, kidney and
spleen at 15 minutes after injection. No signiﬁcant change
in the uptake of 99mTc-tannic acid at 2h after injection was
observed when compared to its previous value. The data
also showed that some organs exhibit signiﬁcant increase of
uptake at 1h after injection like kidney and muscle. On the
other hand, signiﬁcant decrease in 99mTc-tannic acid uptake
was observed in blood, heart, spleen and lung at the same
time. At 2h after injection, the majority of organs showed
signiﬁcant decrease in uptake of 99mTc-tannic acid.
(2) Oral Administration in Ulcer Bearing Mice. After oral
administration of 99mTc-tannic acid in ulcer-bearing mice, it
was found that 99mTc-tannic acid uptake was the greatest in
blood,liverandstomach(8.5,3.5and18,resp.)at15minutes
after injection and lowest in heart, spleen, lung and kidney
(1, 1, 2.1 and 1, resp.) (Table 4) .T h eu p t a k eo f99mTc-tannic
acid in stomach was signiﬁcantly increased with time at 1h
after injection, as it was 50% per g, then, it was signiﬁcantly
decreased to 20% at 2h after injection.
4. Conclusion
Incorporation of 99mTc-tannic acid to an ulcer was achieved
by oral administration of 99mTc-tannic acid in ulcer-bearing
mice. The appropriate conditions for labeling (95.5% yield)
were 100µg tannic acid, 50µg tin as reducing agent, at pH 7,
atroomtemperatureand30minutesreactiontime.Thegreat
incorporation of 99mTc-tannic acid in ulcer sites facilitates
stomach imaging. 99mTc-tannic acid was found to be highly
localized in ulcer sites specially after oral adminstration. In
conclusion, this study demonstrates a hopeful approach for
stomach ulcer imaging.
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